SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancie

SPV, CERO 1236, to raise capital directly into subsidiary and not dilute existing SRX Global shareholders